Advancements in Multiple Myeloma Treatment: Frontline Approaches and Therapies for Early Relapse : Episode 6
Clinical Experience in CAR-T-Cell Therapy in Early Relapsed MM and Insights From the CARTITUDE-4 Trial
Panelists discuss how chimeric antigen receptor (CAR) T-cell therapy in early relapsed multiple myeloma can provide deep and durable responses for eligible patients, though patient selection, timing of referral, manufacturing logistics, and management of adverse effects remain important considerations in optimizing outcomes.
Video content above is prompted by the following:
- What has been your experience with using CAR T-cell therapy in patients with early relapsed multiple myeloma?
- How does CAR T-cell therapy compare with other available second-line treatments?
Recent Videos
Related Content
